SHH · 600276.SS
Jiangsu Hengrui Medicine Co., Ltd.
CN¥49.03+CN¥0.41 (+0.84%)
Jiangsu Hengrui Medicine Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.52% below the high.
Loading market information…
SHH · 688235.SS · CNY
Stock price, earnings
Quote as of Oct 30, 2026, 03:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
BeOne Medicines Ltd. Class A’s quoted price sits in the lower half of its reported 52-week range, 19.93% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
BeOne Medicines Ltd. Class A’s next earnings report is currently expected on Nov 6, 2026, with estimated earnings per share of CN¥0.97. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow BeOne Medicines Ltd. Class A’s reporting calendar.
THE COMPANY BEHIND THE TICKER
BeOne Medicines AG, an oncology-focused enterprise headquartered in Basel, Switzerland, was established in 2010. This company is actively involved in the exploration and advancement of a diverse range of therapeutic solutions for cancer patients across key global regions, including the United States, China, Europe, and other international markets. Its current commercial portfolio features several significant treatments: BRUKINSA: A small molecule designed to inhibit Bruton's Tyrosine Kinase (BTK), indicated for various blood cancers. TEVIMBRA: An anti-PD-1 antibody immunotherapy utilized in the treatment of both solid tumors and blood cancers. PARTRUVIX: A selective small molecule inhibitor targeting the PARP1 and PARP2 enzymes, currently undergoing evaluation both as a standalone therapy and in combination approaches for different solid tumors. Beyond these marketed products, BeOne Medicines maintains a robust pipeline of clinical-stage assets. These encompass a broad spectrum of novel agents, such as small molecule inhibitors (e.g., targeting Bcl-2, BTK, TIGIT, MAT2A, PRMT5, KRAS, CDK4, CDK2, IRAK4, HPK-1), advanced antibody-drug conjugates (ADCs) aimed at various targets (e.g., B7H3, FGFR2b, CEA, B7H4), and sophisticated bispecific antibodies (e.g., HER2-targeted, anti-GPC3x4-1BB, anti-MUC1xCD16A, anti-EGFRxMET). Additionally, the company is progressing multiple research programs within its preclinical development phase. To bolster its research and development initiatives, BeOne Medicines has established strategic alliances with prominent pharmaceutical entities, including Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company, initially known as BeiGene, Ltd., is slated to officially adopt the name BeOne Medicines AG in May 2025.
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:11 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 7, 2025 | -CN¥0.07+80.26% vs estimate | CN¥8.14B-0.66% vs estimate |
|---|
| Q4 2024 | Feb 24, 2025 | -CN¥0.86-41.34% vs estimate | CN¥8.23B+8.48% vs estimate |
|---|
| Q3 2024 | Nov 13, 2024 | -CN¥0.64-23.08% vs estimate | CN¥7.03B-2.08% vs estimate |
|---|
THE ANALYST VIEW
13 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥49.03+CN¥0.41 (+0.84%)
Jiangsu Hengrui Medicine Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.52% below the high.
HK$81.65+HK$0.05 (+0.06%)
Innovent Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.55% below the high.
HK$436.80-HK$1.00 (-0.23%)
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 22.35% below the high.
CN¥95.50+CN¥1.88 (+2.01%)
RemeGen Co. Ltd. Class A’s quoted price sits in the lower half of its reported 52-week range, 39.48% below the high.
CN¥83.15+CN¥0.12 (+0.14%)
Shanghai Allist Pharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 39.88% below the high.
CN¥29.89+CN¥0.05 (+0.17%)
Shanghai Junshi Biosciences Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 35.79% below the high.
CN¥85.00+CN¥0.80 (+0.95%)
Suzhou Zelgen Biopharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 46.88% below the high.
CN¥35.54+CN¥0.01 (+0.03%)
Evopoint Biosciences Co. Ltd.’s quoted price sits in the lower half of its reported 52-week range, 55.0% below the high.
